跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RYBREVANT - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
RYBREVANT
Authorized
STANDARD
RYBREVANT
Janssen Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
a9372915c0933301
Company
Janssen Inc
Type
Standard
Approval Details
Approval Id
a9372915c0933301
Drug Approval Canada Name
RYBREVANT
Product Name
RYBREVANT
Status
Marketed
Status Date
2022-04-26
Original Market Date
2022-04-26
Din
02526182
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01FX18 AMIVANTAMAB
Atc Name
l 01 fx 18
Aig Number
0163501001
Company Name
Janssen Inc
Company Address
19 Green Belt Drive, Toronto, Ontario, Canada, M3C 1L9
Company Detail Path
/organization/janssen-inc
Company Information
Pharmaceutical Company Name
Janssen Inc
Country Name
Canada
Province Name
Ontario
City Name
north york,ontario,country_ca
Address
19 Green Belt Dr
Active Ingredients
AMIVANTAMAB
350 MG / 7 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
a9372915c0933301
Type
Standard
Back to Health Canada Approvals